Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The mechanisms of drug resistance development in the Plasmodium falciparum parasite to lumefantrine (LUM), commonly used in combination with artemisinin, are still unclear. We assessed the polymorphisms of Pfmspdbl2 for associations with LUM activity in a Kenyan population. MSPDBL2 codon 591S was associated with reduced susceptibility to LUM (P = 0.04). The high frequency of Pfmspdbl2 codon 591S in Kenya may be driven by the widespread use of lumefantrine in artemisinin combination therapy (Coartem).

Original publication




Journal article


Antimicrob Agents Chemother

Publication Date





1770 - 1775


Antimalarials, Artemether, Lumefantrine Drug Combination, Artemisinins, Codon, Drug Combinations, Drug Resistance, Ethanolamines, Fluorenes, Humans, Kenya, Lumefantrine, Malaria, Falciparum, Plasmodium falciparum, Polymorphism, Genetic, Protozoan Proteins